Related Topics

    Stewart: News Releases & Feature Stories

    Researchers map "genomic landscape" of childhood adrenocortical tumors for the first time

    St. Jude Children’s Research Hospital scientists identify key molecular events in pediatric adrenocortical tumors; findings could help clinicians identify most malignant subtypes and lead to better treatment. (Raul Ribeiro, MD; Jinghui Zhang, PhD; and Gerard Zambetti, PhD)

    Digging deeper to save lives and hearing

    Cisplatin is one of the most widely used anti-cancer drugs. Many patients treated with the drug also have serious side effects like hearing loss.

    Inherited gene variations tied to treatment-related hearing loss in cancer patients

    St. Jude Children’s Research Hospital scientists have identified inherited genetic variations associated with hearing loss in young cancer patients treated with cisplatin, a drug widely used to treat adults with cancer. (Jun J. Yang, PhD, Clinton Stewart, PhD, and Giles Robinson, MD)

    Low doses of drug help kids avoid genetic test

    St. Jude investigators have shown that when the cancer drug irinotecan is given in low doses for multiple days, it eliminates the need to perform costly genetic testing that would delay treatment.

    Scientists gain new insight into drug pump in brain

    St. Jude researchers have found evidence in a mouse model that simultaneous therapy with a drug that regulates movement of topotecan from the bloodstream can reduce its concentration in the cerebrospinal fluid (CSF).

    Simplifying therapy for neuroblastoma

    The best dose of a chemotherapy drug for one child is not necessarily the best dose for another. St. Jude scientists are simplifying individualized therapy for children with cancer.

    Fewer blood samples needed to check drug level

    A team of researchers at St. Jude has figured out how to minimize the number of times children receiving the cancer drug topotecan must have blood samples drawn when performing pharmacokinetic studies, while ensuring accurate results.

    Fine-tuning cancer drug concentrations in neuroblastoma

    Monitoring and fine tuning the levels of the cancer drug topotecan in children with neuroblastoma holds promise for maximizing the drug's effectiveness while reducing its toxicity.